Mark Erlander, PhD, Chief Scientific Officer, Trovagene, discusses a study looking at the association between ctDNA KRAS mutation levels and outcomes in patients with non-resectable pancreatic cancer.
Mark Erlander, PhD
Advertisement
Articles by Mark Erlander, PhD
Advertisement
Latest Updated Articles
KRAS and Outcomes in Pancreatic CancerApril 21st 2015
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
2
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
3
Sofetabart Mipitecan Elicits Responses Across FRα Levels in Ovarian Cancer
4
FDA Grants Traditional Approval to Pembrolizumab in TMB-High Solid Tumors
5